GUFIC BIOSCIENCES Latest Share Price (GUFICBIO)
TODAY IN ONE LINE
GUFICBIO rose 1.3% on average volume, outperforming Nifty's 0.1% move, reaching near its 52-week high of ₹453.9.
With a market cap of ₹4,431.48 Cr., it trades at a P/E of 60.03. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
GUFIC BIOSCIENCES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 183.1% YoY
- ●High Promoter HoldingPromoters hold 72.5% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 9.7%
- ●Expensive ValuationTrading at a high P/E ratio of 61.7x
Latest GUFIC BIOSCIENCES News
What changed recently?
Recent events, corporate actions, and announcements.
GUFIC BIOSCIENCES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for GUFIC BIOSCIENCES, framed against the sector median so the premium or discount is obvious at a glance.
GUFIC BIOSCIENCES trades at a P/E of 60.03× and P/B of 6.63×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
GUFIC BIOSCIENCES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for GUFIC BIOSCIENCES — derived from the latest tape, not yesterday's close.
GUFIC BIOSCIENCES last traded at ₹444.9 with an intraday range of ₹437.15–₹447.2 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹444.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 469.12 | +24.22 | +5.44% |
| R3 | 459.07 | +14.17 | +3.18% |
| R2 | 453.13 | +8.23 | +1.85% |
| R1 | 449.02 | +4.12 | +0.93% |
| PIVOT | 443.08 | -1.82 | -0.41% |
| CURRENT | 444.90 | — | — |
| S1 | 438.97 | -5.93 | -1.33% |
| S2 | 433.03 | -11.87 | -2.67% |
| S3 | 428.92 | -15.98 | -3.59% |
| S4 | 418.87 | -26.03 | -5.85% |
GUFICBIO is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹437.15–₹447.2
Trading Inside opening range
GUFIC BIOSCIENCES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for GUFIC BIOSCIENCES — consolidated or standalone — with margins, YoY growth and key ratios inline.
GUFIC BIOSCIENCES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,431.48 Cr. and reported EPS of ₹2.24.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 820 | 944 ▲ 15.2% |
| Sales Growth YoY %Derived | 1.63% | 15.15% |
| Other Income | 4 | 3 ▼ 26.7% |
| Total Income | 823 | 947 ▲ 15.0% |
| 375 | 421 ▲ 12.4% | |
| Gross ProfitDerived | 445 | 523 ▲ 17.5% |
| Gross Margin %Derived | 54.29% | 55.38% |
| 310 | 371 ▲ 19.7% | |
| EBITDA (Operating Profit)Derived | 135 | 151 ▲ 12.4% |
| OPM %Derived | 16.43% | 16.03% |
| 44 | 67 ▲ 52.7% | |
| Profit Before Tax (PBT) | 94 | 87 ▼ 8.1% |
| 24 | 22 ▼ 8.8% | |
| Effective Tax %Derived | 26.02% | 25.81% |
| Total Profit for Period | 70 | 64 ▼ 7.8% |
| Less: Non-controlling Interests | -0 | -0 ▼ 150.0% |
| Net Profit (Owner's PAT)Derived | 70 | 64 ▼ 7.8% |
| Net Profit Margin %Derived | 8.50% | 6.80% |
| PAT Growth YoY %Derived | -19.14% | -7.80% |
| Earnings Per Share (EPS ₹) | 6.95 | 6.40 ▼ 7.9% |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 491.0% |
| Total Expenses (incl. D&A & Interest) | 729 | 860 ▲ 17.9% |
| Material Cost % of RevenueDerived | 41.99% | 45.06% |
| Employee Cost % of RevenueDerived | 15.50% | 16.07% |
| Other Cost % of RevenueDerived | 22.37% | 23.28% |
| Interest Coverage (x)Derived | 4.92x | 3.29x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 807 | 820 ▲ 1.6% | 944 ▲ 15.2% | |
| Sales Growth YoY %Derived | — | 1.63% | 15.15% | |
| Other Income | 2 | 4 ▲ 66.6% | 3 ▼ 26.7% | |
| Total Income | 809 | 823 ▲ 1.8% | 947 ▲ 15.0% | |
390 | 375 ▼ 3.9% | 421 ▲ 12.4% | ||
| Gross ProfitDerived | 417 | 445 ▲ 6.8% | 523 ▲ 17.5% | |
| Gross Margin %Derived | 51.67% | 54.29% | 55.38% | |
271 | 310 ▲ 14.6% | 371 ▲ 19.7% | ||
| EBITDA (Operating Profit)Derived | 146 | 135 ▼ 7.7% | 151 ▲ 12.4% | |
| OPM %Derived | 18.08% | 16.43% | 16.03% | |
32 | 44 ▲ 36.4% | 67 ▲ 52.7% | ||
| Profit Before Tax (PBT) | 116 | 94 ▼ 18.6% | 87 ▼ 8.1% | |
30 | 24 ▼ 17.1% | 22 ▼ 8.8% | ||
| Effective Tax %Derived | 25.53% | 26.02% | 25.81% | |
| Total Profit for Period | 86 | 70 ▼ 19.1% | 64 ▼ 7.8% | |
| Less: Non-controlling Interests | — | -0 | -0 ▼ 150.0% | |
| Net Profit (Owner's PAT)Derived | 86 | 70 ▼ 19.1% | 64 ▼ 7.8% | |
| Net Profit Margin %Derived | 10.68% | 8.50% | 6.80% | |
| PAT Growth YoY %Derived | — | -19.14% | -7.80% | |
| Earnings Per Share (EPS ₹) | 8.59 | 6.95 ▼ 19.1% | 6.40 ▼ 7.9% | |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% | 10 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 68.4% | 0 ▲ 491.0% | |
| Total Expenses (incl. D&A & Interest) | 693 | 729 ▲ 5.2% | 860 ▲ 17.9% | |
| Material Cost % of RevenueDerived | 42.31% | 41.99% | 45.06% | |
| Employee Cost % of RevenueDerived | 13.59% | 15.50% | 16.07% | |
| Other Cost % of RevenueDerived | 19.99% | 22.37% | 23.28% | |
| Interest Coverage (x)Derived | 8.39x | 4.92x | 3.29x |
GUFIC BIOSCIENCES segment analysis : revenue and profit mix.
Disclosed business segments at GUFIC BIOSCIENCES with their share of revenue and profit, switchable between consolidated and standalone reporting.
GUFIC BIOSCIENCES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for GUFIC BIOSCIENCES.
Our AI distills the core fundamental drivers supporting GUFIC BIOSCIENCES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
GUFIC BIOSCIENCES's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 72.5% ensures long-term management alignment with shareholders.
TTM revenue growth of 22.8% YoY indicates expanding market demand and revenue traction.
Operating margin of 12.77% demonstrates efficient cost control and operational discipline.
Positive net operating cash flow of ₹59.12 Cr supports operational liquidity and sustainability.
Moderate debt-to-equity ratio of 0.61x reflects manageable leverage and financial stability.
Key Risks.
Latest quarterly EPS grew 183.6% YoY, but PAT declined 0.66% YoY, signaling profitability deterioration.
High P/E ratio of 61.70x signals significant overvaluation relative to current earnings power.
Net profit margin of 6.80% lags peer median of 14.0%, indicating weak pricing power.
Dividend yield of 0.05% offers minimal income return to equity investors.
ROE of 9.66% and ROCE of 9.43% lag peer medians, reflecting suboptimal capital deployment.
Flip Conditions.
Valuation risk. a P/E above 78 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.08. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
GUFIC BIOSCIENCES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — GUFIC BIOSCIENCES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
GUFIC BIOSCIENCES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for GUFIC BIOSCIENCES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
GUFIC BIOSCIENCES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for GUFIC BIOSCIENCES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in GUFIC BIOSCIENCES stood at 51.2% of traded volume, against a 20-day average of 49.6%.
GUFIC BIOSCIENCES announcements: results, concalls, ratings, M&A.
Filings GUFIC BIOSCIENCES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
GUFIC BIOSCIENCES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 118 documents below.
Shareholders meeting
Gufic Biosciences Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 04, 2026
General Updates
Gufic Biosciences Limited has informed the Exchange about Promotion and Change in Designation of Senior Management Personnel
Analysts/Institutional Investor Meet/Con. Call Updates
Gufic Biosciences Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and…
Analysts/Institutional Investor Meet/Con. Call Updates
Gufic Biosciences Limited has informed the Exchange about Link of Recording
Investor decks & rating reports.
General Updates
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
GUFIC BIOSCIENCES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue GUFIC BIOSCIENCES has declared, sequenced by announce and record date.
GUFIC BIOSCIENCES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About GUFIC BIOSCIENCES: business, sector, key facts.
What GUFIC BIOSCIENCES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
GUFIC BIOSCIENCES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GUFICBIO, BSE: 509079.
Gufic Biosciences Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global reach encompassing Africa, Asia, Europe, Australia, North America, and South America. Their core business revolves around the manufacturing and marketing of a diverse range of pharmaceutical products. This includes active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services.
A significant portion of Gufic's manufacturing focuses on APIs and bulk drugs. Their production capabilities span several crucial therapeutic areas. Specifically, they produce antifungals, anesthetics, and immunosuppressants, along with key intermediates used in the synthesis of antifungals. This demonstrates a strong presence in the manufacturing of essential raw materials for the pharmaceutical industry, not just finished products.
Beyond APIs and bulk drugs, Gufic also manufactures lyophilized injections. This advanced pharmaceutical formulation is utilized across a wide spectrum of therapeutic applications. Their lyophilized injection portfolio includes antibiotics, antifungals, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs). This highlights Gufic's ability to deliver a variety of finished dosage forms catering to different patient needs.
In addition to its core API and injection manufacturing, Gufic markets several branded pharmaceutical product lines. These include Criticare, Criticare Life, Ferticare, and Spark Pharmaceuticals, each likely targeting specific therapeutic segments. Furthermore, the company extends its reach into herbal products, aesthetic products under the Aesthaderm brand, Gufic Stridden, and personal care products, diversifying its market presence beyond its pharmaceutical core competencies.
Gufic's distribution network extends to a broad range of customers. The company supplies its products directly to hospital chains and medical facilities, indicating a significant focus on institutional sales and a strong presence within the healthcare system. Their global reach suggests that they either have a robust export division or operate through strategic partnerships in international markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about GUFIC BIOSCIENCES (GUFICBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of GUFIC BIOSCIENCES (GUFICBIO)?
The current share price of GUFIC BIOSCIENCES (GUFICBIO) is ₹444.90. Today, the stock has gained by ₹5.55 (1.26%), trading in a range of ₹437.15 to ₹447.20. The stock opened at ₹440.50 with a trading volume of 88,007 shares.
02Is GUFIC BIOSCIENCES stock a good investment for long-term?
GUFIC BIOSCIENCES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,431.48 Cr., P/E ratio of 60.03, ROE of 9.66%, and ROCE of 9.43%. The dividend yield stands at 0.05%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of GUFIC BIOSCIENCES stock?
The 52-week high price of GUFIC BIOSCIENCES (GUFICBIO) is ₹453.95, while the 52-week low is ₹268.00. Currently trading at ₹444.90, the stock is 66.01% above its 52-week low and 1.99% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy GUFIC BIOSCIENCES stock at the current price?
Whether to buy GUFIC BIOSCIENCES stock at ₹444.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 60.03 and P/B ratio of 6.63. Today's performance shows a gain of 1.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of GUFIC BIOSCIENCES and when is the next dividend?
GUFIC BIOSCIENCES offers a dividend yield of 0.05%, which means for every ₹100 invested at the current price of ₹444.90, you can expect to receive approximately ₹0.05 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of GUFIC BIOSCIENCES?
GUFIC BIOSCIENCES's key financial metrics include: P/E Ratio: 60.03, P/B Ratio: 6.63, ROE: 9.66%, ROCE: 9.43%, Dividend Yield: 0.05%, EPS: ₹2.24, Book Value: ₹66.31, and Debt-to-Equity: 0.58. The company's market cap stands at ₹4,431.48 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is GUFIC BIOSCIENCES stock performing today in the market?
GUFIC BIOSCIENCES stock opened at ₹440.50 and is currently trading at ₹444.90, showing a gain of ₹5.55 (1.26%). The intraday high is ₹447.20 and low is ₹437.15. The trading volume stands at 88,007 shares, indicating moderate market participation today.
08What is the P/E ratio of GUFIC BIOSCIENCES and what does it indicate?
GUFIC BIOSCIENCES has a Price-to-Earnings (P/E) ratio of 60.03, which means investors are willing to pay 60.03 for every ₹1 of earnings. With an EPS of ₹2.24, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about GUFIC BIOSCIENCES (GUFICBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.